Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
Syst Rev. 2021 May 5;10(1):135. doi: 10.1186/s13643-021-01686-6.
Despite prophylactic human papillomavirus (HPV) vaccination being a safe, effective and cost-effective public health intervention for the prevention of cervical cancer, the HPV vaccine is not actively recommended or promoted by the Ministry of Health Labour and Welfare in Japan. With already very low levels of cervical screening below 30%, and vaccination levels that are below levels that award any population effect at 0.3% of the eligible population, cervical cancer mortality is higher than other similar high-income countries at 4.4/100,000 (2900) deaths per year in 2015. There is limited population-based or nationally representative data for HPV genotype distribution in Japan, thus making an assessment of the burden of vaccine-preventable cervical cancer difficult. Therefore, this systematic review and meta-analysis aims to determine the HPV genotype prevalence and age distribution of HPV infection in women with a cytological or histological diagnosis of normal through cervical cancer in Japan. We anticipate this information will guide and enhance programme interventions to reduce vaccine-preventable cervical cancer mortality in Japan.
PubMed, Embase and the Japan Medical Abstract Society Database will be searched from the date of establishment to March 2021 to identify original research articles that report the prevalence of HPV genotypes in Japanese women with normal cervical cytology, low grade, high grade and cancerous cervical lesions. No exclusion criteria relating to language or publication date will be applied. The quality of the studies will be assessed using the Joanna Briggs checklist for prevalence studies. Randomised control trials, cohort studies, cross-sectional and prevalence studies will be considered eligible. Study findings will be combined using a traditional random-effects or fixed-effects meta-analysis to summarise pooled prevalence and 95% confidence intervals depending on heterogeneity. Subgroup analyses and meta-regression will be used to investigate heterogeneity, and sensitivity analyses will be conducted to assess the robustness of the findings.
To our knowledge, this is the first systematic review protocol that includes both Japanese and English peer-reviewed articles for the determination of genotype-specific HPV prevalence in cytological or histological confirmed normal cervical specimens, low- and high-grade intraepithelial lesions and cervical cancers by age in Japan. We anticipate this information will guide and enhance programme interventions to reduce vaccine-preventable cervical cancer mortality in Japan.
PROSPERO CRD42018117596.
尽管预防性人乳头瘤病毒(HPV)疫苗接种是预防宫颈癌的一种安全、有效且具有成本效益的公共卫生干预措施,但日本厚生劳动省并不积极推荐或推广 HPV 疫苗。日本的宫颈癌筛查率已经非常低,低于 30%,疫苗接种率也低于能够对 0.3%符合条件人群产生任何群体效果的水平,因此,宫颈癌死亡率高于其他类似的高收入国家,2015 年每年每 10 万人中有 4.4 人(2900 人)死于宫颈癌。日本 HPV 基因型分布的基于人群或全国代表性数据有限,因此难以评估可通过疫苗预防的宫颈癌的负担。因此,本系统评价和荟萃分析旨在确定日本细胞学或组织学诊断为正常至宫颈癌的女性中 HPV 感染的 HPV 基因型流行率和年龄分布。我们预计这些信息将指导和加强计划干预措施,以降低日本可通过疫苗预防的宫颈癌死亡率。
将从建立日期到 2021 年 3 月在 PubMed、Embase 和日本医学摘要学会数据库中搜索,以确定报告日本正常宫颈细胞学、低级别、高级别和癌性宫颈病变女性 HPV 基因型流行率的原始研究文章。不会应用与语言或出版日期有关的排除标准。使用 Joanna Briggs 清单评估研究的质量,用于流行率研究。合格的研究包括随机对照试验、队列研究、横断面研究和流行率研究。将使用传统的随机效应或固定效应荟萃分析合并研究结果,以汇总汇总流行率和 95%置信区间,具体取决于异质性。将进行亚组分析和荟萃回归以调查异质性,并进行敏感性分析以评估结果的稳健性。
据我们所知,这是第一项系统评价方案,包括日本和英语同行评审文章,以确定日本细胞学或组织学证实的正常宫颈标本、低级别和高级别上皮内病变以及宫颈癌的年龄特异性 HPV 流行率。我们预计这些信息将指导和加强计划干预措施,以降低日本可通过疫苗预防的宫颈癌死亡率。
PROSPERO CRD42018117596。